Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...

Researchers at Virginia Polytechnic Institute and State University took 20 people living with obesity (half on GLP-1s like ...

Welcome to this week’s Food Exec Brief, a roundup of the most important news shaping food and beverage manufacturing, from ...

Why is the Supreme Court’s directive to notify a new Saranda wildlife sanctuary important for your UPSC exam? What ...

Clinical studies have shown that participants using Tirzepatide experienced up to 22% body weight reduction over 72 weeks, ...

Pakistan’s healthcare landscape has entered a pivotal phase in the management of diabetes and obesity. For years, advanced ...

US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...

People without diabetes who receive GLP-1 receptor agonists for the treatment of overweight or obesity face a reduced risk of ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Pakistan's healthcare sector has entered a transformative phase in the management of diabetes and obesity, as locally ...

Cipla enters obesity and diabetes drug market with Eli Lilly's tirzepatide 'Yurpeak'; Nuvama retains 'Hold' on Cipla stock, ...

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...